Related Experiment Video
Updated: Mar 19, 2026
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
576
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases
Joana Torres1,2, Flavio Caprioli3, Konstantinos H Katsanos4
1Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal.
Journal of Crohn'S & Colitis
|June 11, 2016
Summary
Identifying high-risk patients with inflammatory bowel diseases [IBD] is crucial for preventing complications. Simple clinical factors can identify these individuals early, guiding proactive management strategies.
Area of Science:
- Gastroenterology
- Clinical Medicine
- Inflammatory Bowel Disease Research
Background:
- Effective management of inflammatory bowel diseases [IBD] requires early identification of patients at high risk for complications.
- Proactive monitoring and treatment are essential for mitigating disease progression and improving patient outcomes.
Purpose of the Study:
- To identify predictors of long-term prognosis in inflammatory bowel diseases [IBD].
- To generate expert consensus statements on identifying high-risk IBD patients.
Main Methods:
- A comprehensive literature review was conducted as part of the IBD Ahead initiative.
- Expert summary statements were developed and refined through national and international meetings involving IBD specialists.
Main Results:
- Young age, extensive disease, deep ulcerations, and specific behaviors (e.g., penetrating/stenosing) indicate high risk in Crohn's disease.
- Extensive colitis, frequent flares, and steroid dependency signal increased colectomy risk in ulcerative colitis.
- Smoking, primary sclerosing cholangitis, and infections can influence disease course; current genetic markers lack clinical utility.
Conclusions:
- Demographic and clinical features can identify high-risk IBD patients at diagnosis and during the disease course.
- Retrospectively identified risk factors require prospective validation.
- Prospective studies are needed to develop predictive algorithms for individual patient risk assessment.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
909
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
909
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
653
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
653
01:21Inflammatory Bowel Disease V: Surgical Management
818
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
818
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
603
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
603
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
716
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
716